Covid-19
Germany approves clinical trial of coronavirus immunity vaccines
Germany has approved clinical trials of multiple vaccines developed by German biotech company, BioNTech, for treatment of coronavirus. Scientists were said to be monitoring the effectiveness of the vaccines in generating immunity against coronavirus. The clinical trial will be starting with 200 participants of 18 to 55 years age bracket.
Statistics from Johns Hopkins University shows that coronavirus has killed over 177,000 people and infected 2.5 million across the world. This was identified to have given impetus to the race to develop vaccines that can contain the spread of coronavirus and the associated deaths across the world.
About 86 teams were identified to be engaged on research and study for coronavirus vaccines across the world.
-
Business6 days agoAbuja gears up for Jetour T2’s rugged-luxury experience
-
News5 days agoUK, Canada pledge closer cooperation on trade, defence and AI
-
Business1 week agoNigeria Business Outlook: Dangote IPO, markets, inflation and naira in focus this week
-
Business1 week agoDangote IPO rush crashes Bamboo login as investors flood platform
-
Business6 days agoTinubu’s economic reforms face public confidence test as cost-of-living crisis persists
-
Business6 days agoDangote: Petrol price gap fuels smuggling as Nigeria faces fresh pump price surge
-
Business3 days ago
Dangote Refinery IPO: Can small investors really make money from the shares?
-
Comments and Issues4 days agoWavy fuel prices and deepening cost-of-living crises in Nigeria